Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating filgotinib in active psoriatic arthritis patients intolerant or inadequate response to biologic DMARD therapy was terminated with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Filgotinib (filgotinib)

Snippet

Sponsor: Gilead Sciences | Conditions: Psoriatic Arthritis | Phase 3 | Status: TERMINATED | Results posted: 2022-03-18